Does the 2017 revision improve the ability of GOLD to predict risk of future moderate and severe exacerbation?
Serhat ErolElif SenYagmur Gizem KilicAhmed YousifOznur Akkoca YildizTuran AcicanSevgi SaryalPublished in: The clinical respiratory journal (2018)
Low FEV1 was an important risk factor for future exacerbations. Downstaging of C1/D1 patients caused heterogeneity in A/B with including patients with low and high risk of future exacerbation. This resulted in a low discriminative power of GOLD 2017 regarding the risk of future exacerbation in groups A and B. This may cause underestimation of disease severity and inadequate treatment especially in A/B patients with low FEV1 .